Benzinga··Bamboo WorksPrecision-Drug Maker Impact Therapeutics Soars 100% in Hong Kong IPO Debut
Impact Therapeutics soared 100% in Hong Kong IPO debut after raising HK$844 million, validating investor appetite for its ovarian cancer drug senaparib despite competitive pressures from AstraZeneca and Hengrui Pharma.
AZNJHPCYIPObiotech